

Correction

Correction: Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

In this article (*Cancer Immunol Res* 2014;2:632–42), which appeared in the July 2014 issue of *Cancer Immunology Research* (1), the panels of Fig. 1 are labeled incorrectly. The grade 4 toxicities should be labeled as A, and the grade 3 toxicities as B; B to G should be labeled C to H. The authors regret this error.

Reference

1. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. *Cancer Immunol Res* 2014;2:632–42.

Published OnlineFirst August 5, 2014.

doi: 10.1158/2326-6066.CIR-14-0141

©2014 American Association for Cancer Research.

Cancer Immunology Research

Correction: Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

Cancer Immunol Res 2014;2:923. Published OnlineFirst August 5, 2014.

Updated version Access the most recent version of this article at:
doi:[10.1158/2326-6066.CIR-14-0141](https://doi.org/10.1158/2326-6066.CIR-14-0141)

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://cancerimmunolres.aacrjournals.org/content/2/9/923.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerimmunolres.aacrjournals.org/content/2/9/923>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.